Lupus Nephritis Correlates with B Cell Interferon-β, Anti-Smith, and Anti-DNA: a Retrospective Study

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2022 Apr 19

PMID 35436902

Authors

Fatima Alduraibi

Huma Fatima

Jennie A Hamilton

W Winn Chatham

Hui-Chen Hsu

John D Mountz

Affiliations

Soon will be listed here.

Abstract

Background: In systemic lupus erythematosus (SLE), detection of interferon-β (IFNβ) in B cells was found to be most prominent in patients with high anti-Smith (Sm) and renal disease, but a mechanistic connection was not clear. The objective of the present study is to determine the association of IFNβ in peripheral blood naïve B cells with the histopathological features of lupus nephritis (LN).

Methods: The percentage of IFNβ cells in IgDCD27 naïve CD19 B cells (B cell IFNβ) among peripheral blood mononuclear cells (PBMCs) from 80 SLE patients were analyzed using flow cytometry. Serological and clinical data were collected. The correlations of B cell IFNβ with LN classification and with histopathological findings (light, electron, and immunofluorescence [IF] microscopic analyses for deposition of IgM, IgG, IgA, C1q, and C3) were determined in 23 available biopsy specimens.

Results: B cell IFNβ is positively associated with anti-Sm (p = 0.001), anti-DNA (p = 0.013), and LN (p < 0.001) but was negatively associated with oral/nasal ulcer (p = 0.003) and photosensitivity (p = 0.045). B cell IFNβ positively correlated with immune complex (IC) deposit in the glomerular basement membrane (GBM) (p = 0.002) but not in the mesangial (p = 0.107) or tubular region (p = 0.313). Patients with high B cell IFNβ had statistically increased development of the proliferative LN (Classes III, IV and/or V), compared to patients with low B cell IFNβ (p < 0.0001). Histopathological features positively associated with increased B cell IFNβ included active glomerular lesions as determined by fibrocellular crescents (p = 0.023), chronic glomerular lesions indicated by segmental sclerosis (p = 0.033), and a membranous pattern of renal damage indicated by spike/holes (p = 0.015).

Conclusion: B cell IFNβ correlates with history of severe LN, glomerular basement membrane (GBM) IC deposition, and anatomical features of both active and chronic glomerular lesions.

Citing Articles

Organ-based characterization of B cells in patients with systemic lupus erythematosus.

Wang Y, Zhao R, Liang Q, Ni S, Yang M, Qiu L Front Immunol. 2025; 16:1509033.

PMID: 39917309 PMC: 11798990. DOI: 10.3389/fimmu.2025.1509033.

Therapeutically targeting proinflammatory type I interferons in systemic lupus erythematosus: efficacy and insufficiency with a specific focus on lupus nephritis.

Lai B, Luo S, Lai J Front Immunol. 2024; 15:1489205.

PMID: 39478861 PMC: 11521836. DOI: 10.3389/fimmu.2024.1489205.

CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.

Abdalhadi H, Chatham W, Alduraibi F Int J Mol Sci. 2024; 25(19).

PMID: 39408836 PMC: 11476835. DOI: 10.3390/ijms251910511.

Clinical characteristics and prognostic value of autoantibody profile in children with monogenic lupus.

Al-Mayouf S, Hamad A, Kaidali W, Alhuthil R, AlSaleem A J Rheum Dis. 2024; 31(3):143-150.

PMID: 38957362 PMC: 11215254. DOI: 10.4078/jrd.2023.0065.

Lupus Nephritis Biomarkers: A Critical Review.

Alduraibi F, Tsokos G Int J Mol Sci. 2024; 25(2).

PMID: 38255879 PMC: 10815779. DOI: 10.3390/ijms25020805.

References

Hartman E, Royen-Kerkhof A, Jacobs J, Welsing P, Fritsch-Stork R . Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and.... Autoimmun Rev. 2018; 17(3):316-322. DOI: 10.1016/j.autrev.2018.01.007. View

Siddiqi K, Wilhelm T, Ulff-Moller C, Jacobsen S . Cluster of highly expressed interferon-stimulated genes associate more with African ancestry than disease activity in patients with systemic lupus erythematosus. A systematic review of cross-sectional studies. Transl Res. 2021; 238:63-75. DOI: 10.1016/j.trsl.2021.07.006. View

Datta D, Contreras A, Grimm M, Waaga-Gasser A, Briscoe D, Pal S . Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J Am Soc Nephrol. 2008; 19(12):2437-46. PMC: 2588111. DOI: 10.1681/ASN.2008040394. View

Hamilton J, Wu Q, Yang P, Luo B, Liu S, Hong H . Cutting Edge: Endogenous IFN-β Regulates Survival and Development of Transitional B Cells. J Immunol. 2017; 199(8):2618-2623. PMC: 5636672. DOI: 10.4049/jimmunol.1700888. View

de Weerd N, Nguyen T . The interferons and their receptors--distribution and regulation. Immunol Cell Biol. 2012; 90(5):483-91. PMC: 7165917. DOI: 10.1038/icb.2012.9. View

Liu Y . Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006; 69(2):213-7. DOI: 10.1038/sj.ki.5000054. View

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

Maria N, Davidson A . Renal Macrophages and Dendritic Cells in SLE Nephritis. Curr Rheumatol Rep. 2017; 19(12):81. DOI: 10.1007/s11926-017-0708-y. View

Li H, Fu Y, Wu Q, Zhou Y, Crossman D, Yang P . Interferon-induced mechanosensing defects impede apoptotic cell clearance in lupus. J Clin Invest. 2015; 125(7):2877-90. PMC: 4563689. DOI: 10.1172/JCI81059. View

10.

Arazi A, Rao D, Berthier C, Davidson A, Liu Y, Hoover P . The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019; 20(7):902-914. PMC: 6726437. DOI: 10.1038/s41590-019-0398-x. View

11.

Lyn-Cook B, Xie C, Oates J, Treadwell E, Word B, Hammons G . Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol Immunol. 2014; 61(1):38-43. DOI: 10.1016/j.molimm.2014.05.001. View

12.

Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R . Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 2008; 152(3):482-7. PMC: 2453201. DOI: 10.1111/j.1365-2249.2008.03646.x. View

13.

Ronnblom L, Alm G . An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 2001; 22(8):427-31. DOI: 10.1016/s1471-4906(01)01955-x. View

14.

Liu Y, Anders H . Lupus nephritis: from pathogenesis to targets for biologic treatment. Nephron Clin Pract. 2014; 128(3-4):224-31. DOI: 10.1159/000368581. View

15.

Baechler E, Batliwalla F, Karypis G, Gaffney P, Ortmann W, Espe K . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5):2610-5. PMC: 151388. DOI: 10.1073/pnas.0337679100. View

16.

Bao L, Cunningham P, Quigg R . Complement in Lupus Nephritis: New Perspectives. Kidney Dis (Basel). 2016; 1(2):91-9. PMC: 4934819. DOI: 10.1159/000431278. View

17.

Ding X, Ren Y, He X . IFN-I Mediates Lupus Nephritis From the Beginning to Renal Fibrosis. Front Immunol. 2021; 12:676082. PMC: 8093624. DOI: 10.3389/fimmu.2021.676082. View

18.

Ronnblom L, Alm G, Eloranta M . The type I interferon system in the development of lupus. Semin Immunol. 2011; 23(2):113-21. DOI: 10.1016/j.smim.2011.01.009. View

19.

Bombardier C, Gladman D, Urowitz M, Caron D, Chang C . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35(6):630-40. DOI: 10.1002/art.1780350606. View

20.

Grootscholten C, Bajema I, Florquin S, Steenbergen E, Peutz-Kootstra C, Goldschmeding R . Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. Nephrol Dial Transplant. 2007; 23(1):223-30. DOI: 10.1093/ndt/gfm555. View